Cardiovascular disease and testosterone therapy in male hypogonadism.

Testosterone exerts complex effects on cardiovascular risk through multiple physiological pathways.

• Preclinical studies suggest testosterone acts on skeletal muscle, cardiomyocytes, vasculature, adipocytes, insulin action, and erythropoiesis.
• These mechanisms collectively produce complex effects on cardiovascular risk rather than a simple protective or harmful profile.
• The review characterizes these effects as acting through at least six distinct tissue/system targets.

Low testosterone has a bidirectional association with cardiometabolic risk in men.

• The association between low testosterone and cardiometabolic risk is described as 'bi-directional', meaning low testosterone may both result from and contribute to cardiometabolic disease.
• Observational studies have reported worse metabolic profiles in men with organic hypogonadism.
• The bidirectional nature complicates causal inference from observational data.

A consistent association between major cardiovascular events and male hypogonadism has not been established.

• Despite observational studies reporting worse metabolic profiles in men with organic hypogonadism, a consistent link to major cardiovascular events is lacking.
• The review explicitly states that 'a consistent association between major cardiovascular events and male hypogonadism has not been established.'
• This finding applies specifically to male hypogonadism as a condition, separate from the effects of testosterone therapy.

Testosterone therapy increases hematocrit, but most studies do not report an increase in venous thromboembolism risk.

• Hematocrit elevation is identified as a known physiological consequence of testosterone therapy.
• Despite hematocrit increases, 'most studies do not report an increase in venous thromboembolism risk.'
• This finding suggests that hematocrit elevation during testosterone therapy may not translate to clinically significant thrombotic events in most patients.

Some observational studies and a small randomized controlled study reported an increased risk of cardiovascular disease with testosterone therapy.

• Both observational studies and at least one small randomized controlled study reported increased cardiovascular disease risk associated with testosterone therapy.
• The review characterizes these studies as either observational in design or small in sample size, implying limitations in their evidence quality.
• These findings are contrasted against more recent data suggesting medium-term cardiovascular safety.

Recent data confirm the medium-term cardiovascular safety of testosterone therapy in middle-aged and older men with low testosterone.

• The review concludes that 'recent data confirm the medium-term cardiovascular safety of testosterone therapy in middle-aged and older men with low testosterone.'
• The safety characterization is specifically qualified as 'medium-term', leaving long-term safety less certain.
• The population for whom safety is confirmed is specifically middle-aged and older men, and the generalizability to younger men is not addressed.
• This conclusion is described as being supported by recent data, suggesting more contemporary studies have helped resolve earlier uncertainty.